Skip to content

ABM for ACO Beneficiaries

Appointment Based Model (ABM) for Accountable Care Organization (ACO) Beneficiaries

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02137551
Acronym
ABM
Enrollment
595
Registered
2014-05-14
Start date
2014-08-31
Completion date
2016-02-29
Last updated
2016-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication Adherence

Keywords

adherence, healthcare costs, appointment based model, accountable care organization

Brief summary

The primary objective of the study is to evaluate how engaging ACO beneficiaries in the appointment based model for one year impacts medication adherence and healthcare costs compared to usual care.

Detailed description

The American Pharmacists Association (APhA) Foundation has partnered with a federally qualified health center (FQHC), a supermarket community pharmacy, and an accountable care organization (ACO) to participate in this ABM for ACO Beneficiaries initiative. The FQHC, El Rio Community Health Center pharmacy, and supermarket pharmacy, Fry's Pharmacy, will serve as implementing pharmacy study sites and will implement the ABM for beneficiaries of the ACO who utilize their pharmacies for medication refill services. The ABM involves synchronizing all medications to come due on the same day of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes. The ACO will provide medical and claims data on enrolled subjects as well as a control group for the intervention population. The APhA Foundation will aggregate intervention, prescription fill, and economic data from the 3 partners in an effort to evaluate the impact of the ABM on healthcare costs and medication adherence. The APhA Foundation has an a priori intent to publish the project results.

Interventions

OTHERABM

The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.

Sponsors

American Pharmacists Association Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Individuals eligible to be enrolled in the study include those who: * Are beneficiaries of the partnering ACO; * Are receiving medical care at El Rio and have been since before May 1, 2013; * Are taking 2 or more medications that are refilled on 30, 60, or 90 day schedules; * Speak English or Spanish; * Are at least 18 years of age; and * Are not institutionalized (i.e., residents of nursing homes, psychiatric institutions, or prisons).

Exclusion criteria

* Use of a legal authorized representative

Design outcomes

Primary

MeasureTime frameDescription
Medical costsBaseline (for the 1 year prior to the enrollment date), During the Patient Care period (approx. 1 year following enrollment)Total medical costs will be collected at baseline for the year prior to enrollment and at the end of the one-year study period for the intervention year.
Pharmacy costsBaseline (at the time of enrollment), During the Patient Care period (approx. 1 year after enrollment)Pharmacy costs will be collected at baseline for the year prior to enrollment and at the end of the one-year study period for the intervention year.
Medication adherenceAt baseline for the one year prior to enrollment, During the 1 year patient care periodProportion of days covered will be calculated to determine medication adherence. Data will be collected on a quarterly basis (every 3 months beginning at enrollment).

Secondary

MeasureTime frameDescription
Identified Medication Related ProblemsDuring the Patient Care period (1 year from enrollment)Information regarding the type of medication related problem identified at each intervention point will be reported to the sponsor on a quarterly basis and during the Patient Care period.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026